Latest news
{{'2026-09-29T10:00:00Z' | dateFormatFilter}}
Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis
{{'2026-09-29T04:35:26Z' | dateFormatFilter}}
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
{{'2026-09-22T12:00:00Z' | dateFormatFilter}}
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
